ABVX Abivax SA

EQS-News: ABIVAX ANNOUNCES THE RELEASE OF ITS 2022 HALF-YEAR FINANCIAL REPORT

EQS-News: ABIVAX / Key word(s): Half Year Results
ABIVAX ANNOUNCES THE RELEASE OF ITS 2022 HALF-YEAR FINANCIAL REPORT

30.09.2022 / 18:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

ABIVAX ANNOUNCES THE RELEASE OF ITS 2022 HALF-YEAR FINANCIAL REPORT

PARIS, France, September 30, 2022 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces the publication of its 2022 half-year financial report.

This document is available in electronic version on the website of the company () and on the website of the French financial markets authority, AMF ().

*****

About Abivax ()

Abivax, a phase 3 clinical stage biotechnology company, is developing novel therapies that modulate the body’s natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, obefazimod (ABX464) to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at . Follow us on Twitter @ABIVAX_.

Contacts

Abivax                 
Communications
Regina Jehle

63		 Investors
LifeSci Advisors
Ligia Vela-Reid

 Press Relations & Investors Europe
MC Services AG
Anne Hennecke

22
Public Relations France
Actifin
Ghislaine Gasparetto

24		 Public Relations France
Primatice
Thomas Roborel de Climens

95		 Public Relations USA     
Rooney Partners LLC
Jeanene Timberlake

30.09.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com

1454659  30.09.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1454659&application_name=news&site_id=research_pool
EN
30/09/2022

Underlying

ABVXAbivax SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abivax SA

 PRESS RELEASE
Free
ABVX ABIVAX SA

EQS-News: Abivax reicht Finanzberichte bei der französischen und der U...

EQS-News: ABIVAX / Schlagwort(e): Jahresbericht Abivax reicht Finanzberichte bei der französischen und der US-amerikanischen Finanzmarktaufsicht ein 05.04.2024 / 22:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Abivax reicht Finanzberichte bei der französischen und der US-amerikanischen Finanzmarktaufsicht ein PARIS, Frankreich, 5. April 2024, 22:00 Uhr MESZ - Abivax SA (Euronext Paris & Nasdaq: ABVX) („Abivax“ oder das „Unternehmen“), ein Biotechnologieunternehmen im klinischen Stadium, das sich auf die Entwicklung von Therapeu...

April 5, 2024 1 DE
 PRESS RELEASE
Free
ABVX ABIVAX SA

EQS-News: Abivax publishes financial reports with the French and U.S. ...

EQS-News: ABIVAX / Key word(s): Annual Report Abivax publishes financial reports with the French and U.S. securities regulatory agencies 05.04.2024 / 22:00 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France, April 5, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to ...

April 5, 2024 1 EN
Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
ABVX ABIVAX SA

Abivax : Full-year results in line - Clinical calendar confirmed

>Financial visibility out to Q4 2025 - The group reported a 2023 operating loss of € 127.4m vs a loss of € 64.8m last year. The difference is explained by operating expenses up by € 63m to € 132m, including € 103.2m (vs €48.3m in 2022) for R&D, € 6.4m (vs € 0m in 2022) for S&M and € 22.4m (vs €7.5m in 2022) for G&A. Cash and cash equivalents were € 261m in December 2023. Including the structured finance with Kreos Capital / Claret, the company is funded until Q4 2025....

04/02/24 April 2, 2024 1 EN
Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
ABVX ABIVAX SA

Abivax : Résultats FY en ligne - calendrier clinique confirmé

>Visibilité financière jusqu’au T4 2025 - La société publie une perte opérationnelle 2023 de 127.4 M€ vs une perte de 64.8 M€ l’année dernière. La différence s’explique par des charges d’exploitation en hausse de 63 M€ pour atteindre 132 M€ dont 103.2 M€ (vs 48.3 M€ en 2022) pour la R&D, 6.4 M€ (vs 0 M€ en 2022) pour les S&M et 22.4 M€ (vs 7.5 M€ en 2022) pour les G&A. La trésorerie était de 261 M€ en décembre 2023. En incluant le financement structuré réalisé auprès ...

04/02/24 April 2, 2024 1 FR
 PRESS RELEASE
Free
ABVX ABIVAX SA

EQS-News: Abivax reports 2023 financial results and operational update

EQS-News: ABIVAX / Key word(s): Annual Results Abivax reports 2023 financial results and operational update 02.04.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and EUR 223.3M initial public offering on the Nasdaq Global Market Sufficient funds to finance operations into Q4 2025, including through the announcement of top-line data from the...

April 2, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch